Novartis Corporation Takes Option on TRANSGENE Cancer Vaccine; Transgene Gets $10 Million, Milestones Could Reach $950 Million

Reuters -- Novartis has taken an exclusive option to develop Transgene's (TRNG.PA) cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French biotechnology company down 12 percent.